MedTrace Logo

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

NCT05842512 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-23

No results posted yet for this study

Summary

Evaluate efficacy and safety of ADI-PEG 20 in patients with NASH

Conditions

  • Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG

ADI-PEG20

Treatment for NASH

OTHER

Placebo

Treatment for NASH

Sponsors & Collaborators

  • Polaris Group

    lead INDUSTRY

Principal Investigators

  • John S Bomalaski · Polaris Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-13
Primary Completion
2027-12-31
Completion
2028-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05842512 on ClinicalTrials.gov